<DOC>
	<DOCNO>NCT02135029</DOCNO>
	<brief_summary>This study multicenter , double blind , active placebo control randomized clinical trial demonstrate superior lipid lower effect Bococizumab ( PF-04950615 ; RN316 ) compare placebo subject statin intolerant .</brief_summary>
	<brief_title>Randomized Clinical Trial Bococizumab ( PF-04950615 ; RN316 ) Subjects Who Are Intolerant Statins</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Hyperlipidemia Statin Intolerant Fasting LDLC &gt; = 70 mg/dL Fasting TG &lt; = 400 mg/dL Pregnant breastfeeding female Cardiovascular cerebrovascular event procedure within 90 day Severe lifethreatening adverse event past use statin Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>statin intolerance</keyword>
</DOC>